目的:观察金龙蛤蚧平喘加味方对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期肺肾气虚证合并骨质疏松患者骨密度(bone mineral density,BMD)及骨代谢生化标志物的影响。方法:选取2022年9月至2023年8月安徽中医...目的:观察金龙蛤蚧平喘加味方对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期肺肾气虚证合并骨质疏松患者骨密度(bone mineral density,BMD)及骨代谢生化标志物的影响。方法:选取2022年9月至2023年8月安徽中医药大学附属滁州中西医结合医院呼吸科门诊及病房收治的COPD稳定期肺肾气虚证合并OP患者58例,根据随机数字表法分为对照组和联合组,每组29例。对照组给予常规西药对症治疗,联合组在对照组治疗的基础上联合金龙蛤蚧平喘加味方治疗。观察两组患者治疗前后肺功能[1秒用力呼气容积(forced expiratory volume in one second,FEV1)用力肺活量(forced vital capacity,FVC)、FEV1/FVC]、COPD评估测试问卷(COPD assessment test,CAT)评分、症状积分、BMD及骨代谢生化标志物[总碱性磷酸酶(alkaline phosphatase,ALP)、骨钙素(osteocalcin,OC)及Ⅰ型胶原C端肽(C-terminal peptide of type 1 collagen,CTX-1)]等指标变化情况。结果:联合组治疗后腰椎BMD高于对照组,差异有统计学意义(P<0.05),股骨颈BMD高于对照组,差异无统计学意义(P>0.05);联合组治疗后ALP、OC、CTX-1水平低于对照组,差异有统计学意义(P<0.05);联合组治疗后腰背疼痛、腰膝酸软、下肢抽筋症状积分均低于对照组,差异有统计学意义(P<0.05);联合组治疗后FEV1高于对照组,CAT评分低于对照组,差异有统计学意义(P<0.05)。结论:金龙蛤蚧平喘加味方能改善COPD稳定期肺肾气虚证合并骨质疏松患者的骨密度、肺功能,降低骨代谢生化标志物ALP、OC、CTX-1水平,减轻患者腰背疼痛、腰膝酸软、下肢抽筋症状。展开更多
Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-tw...Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-two patients with hepatocellular carcinoma were randomly divided into the control group and experimental group. On the first day after TACE, the experimental group started receiving four Jinlong capsules orally three times daily, whereas the control group did not receive the treatment.Results The incidences of erythropenia and thrombocytopenia in the experimental group was lower than those in the control group(P = 0.040 and 0.033, respectively). The differences in serum levels of aminotransferase, albumin, potassium, and sodium between the two groups were significant(P = 0.034, 0.034, 0.013, and 0.044, respectively). The mean durations of stomachache and abdominal distension in the experimental group was significantly shorter than those in the control group(P = 0.004 and 0.021, respectively). However, there were no significant differences in the incidences of nausea, fever, and vomiting between the two groups(P = 0.490, 0.495, and 0.585, respectively). Conclusion The reduction in the incidence rate and duration of partial adverse reactions after TACE was observed in hepatocellular carcinoma patients treated with Jinlong capsule compared to untreated patients, suggesting possible beneficial effects exerted by Jinlong capsule on the reduction of TACE-induced liver damage, thereby improving liver function and, consequently, the quality of life.展开更多
文摘目的:观察金龙蛤蚧平喘加味方对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期肺肾气虚证合并骨质疏松患者骨密度(bone mineral density,BMD)及骨代谢生化标志物的影响。方法:选取2022年9月至2023年8月安徽中医药大学附属滁州中西医结合医院呼吸科门诊及病房收治的COPD稳定期肺肾气虚证合并OP患者58例,根据随机数字表法分为对照组和联合组,每组29例。对照组给予常规西药对症治疗,联合组在对照组治疗的基础上联合金龙蛤蚧平喘加味方治疗。观察两组患者治疗前后肺功能[1秒用力呼气容积(forced expiratory volume in one second,FEV1)用力肺活量(forced vital capacity,FVC)、FEV1/FVC]、COPD评估测试问卷(COPD assessment test,CAT)评分、症状积分、BMD及骨代谢生化标志物[总碱性磷酸酶(alkaline phosphatase,ALP)、骨钙素(osteocalcin,OC)及Ⅰ型胶原C端肽(C-terminal peptide of type 1 collagen,CTX-1)]等指标变化情况。结果:联合组治疗后腰椎BMD高于对照组,差异有统计学意义(P<0.05),股骨颈BMD高于对照组,差异无统计学意义(P>0.05);联合组治疗后ALP、OC、CTX-1水平低于对照组,差异有统计学意义(P<0.05);联合组治疗后腰背疼痛、腰膝酸软、下肢抽筋症状积分均低于对照组,差异有统计学意义(P<0.05);联合组治疗后FEV1高于对照组,CAT评分低于对照组,差异有统计学意义(P<0.05)。结论:金龙蛤蚧平喘加味方能改善COPD稳定期肺肾气虚证合并骨质疏松患者的骨密度、肺功能,降低骨代谢生化标志物ALP、OC、CTX-1水平,减轻患者腰背疼痛、腰膝酸软、下肢抽筋症状。
基金Supported by a grant from the Scientific Innovation Foundation of Xinjiang Medical University(No.XJC2013118)
文摘Objective The aim of this study was to analyze whether Jinlong capsule could decrease adverse reactions after transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma. Methods Eighty-two patients with hepatocellular carcinoma were randomly divided into the control group and experimental group. On the first day after TACE, the experimental group started receiving four Jinlong capsules orally three times daily, whereas the control group did not receive the treatment.Results The incidences of erythropenia and thrombocytopenia in the experimental group was lower than those in the control group(P = 0.040 and 0.033, respectively). The differences in serum levels of aminotransferase, albumin, potassium, and sodium between the two groups were significant(P = 0.034, 0.034, 0.013, and 0.044, respectively). The mean durations of stomachache and abdominal distension in the experimental group was significantly shorter than those in the control group(P = 0.004 and 0.021, respectively). However, there were no significant differences in the incidences of nausea, fever, and vomiting between the two groups(P = 0.490, 0.495, and 0.585, respectively). Conclusion The reduction in the incidence rate and duration of partial adverse reactions after TACE was observed in hepatocellular carcinoma patients treated with Jinlong capsule compared to untreated patients, suggesting possible beneficial effects exerted by Jinlong capsule on the reduction of TACE-induced liver damage, thereby improving liver function and, consequently, the quality of life.
